Urothelial Bladder Cancer Treatment in Singapore

Urothelial bladder cancer treatment encompasses a range of medical and surgical interventions designed to eliminate or control cancer cells originating in the urothelium (the inner lining of the bladder). This type of cancer, also known as transitional cell carcinoma, accounts for approximately 90% of all bladder cancers. Treatment approaches vary based on the cancer’s stage, grade, and whether it has invaded the bladder muscle wall.

The primary goal of treatment is to remove or destroy cancer cells while preserving bladder function when feasible. For non-muscle invasive bladder cancer (NMIBC), treatments focus on removing tumours and preventing recurrence through intravesical therapy. Muscle-invasive bladder cancer (MIBC) requires more extensive intervention, potentially including radical surgery, chemotherapy, or radiation therapy. Treatment selection depends on tumour characteristics, patient health status, and individual preferences regarding quality of life considerations.

Ideal Candidates

• Patients with confirmed urothelial bladder cancer diagnosis through cystoscopy and biopsy
• Individuals with adequate kidney function to tolerate certain chemotherapy regimens
• Patients with sufficient overall health status to undergo planned treatments
• Those with localised disease confined to the bladder or regional lymph nodes
• Individuals committed to regular follow-up surveillance protocols
• Patients without contraindications to specific treatment modalities
• Those with realistic expectations about treatment outcomes and potential side effects

Contraindications

• Severe kidney dysfunction that precludes certain chemotherapy options
• Significant cardiovascular disease that increases surgical risks
• Active uncontrolled infections requiring resolution before treatment
• Bleeding disorders that complicate surgical interventions
• Previous pelvic radiation that limits treatment options
• Certain immunodeficiency conditions affecting immunotherapy eligibility
• Pregnancy (for many systemic treatments)

The determination of treatment suitability requires careful assessment by a urologist, often in consultation with oncologists and other specialists. Each patient’s unique medical history, cancer characteristics, and personal circumstances influence the most appropriate treatment approach.

Transurethral Resection of Bladder Tumour (TURBT)

TURBT serves as both a diagnostic and therapeutic procedure for bladder cancer. Using a specialised instrument called a resectoscope inserted through the urethra, the urologist in Singapore removes visible tumours from the bladder wall. This minimally invasive approach allows for complete tumour removal in many non-muscle invasive cases while preserving bladder function. The procedure takes 30–90 minutes and can be repeated if new tumours develop..

Intravesical Therapy

Following TURBT for non-muscle invasive bladder cancer, intravesical therapy delivers medication directly into the bladder through a catheter. Bacillus Calmette-Guérin (BCG) immunotherapy stimulates the immune system to attack remaining cancer cells, while intravesical chemotherapy using agents like mitomycin C directly destroys cancer cells. Treatment schedules involve weekly installations for six weeks, followed by maintenance therapy for responsive patients.

Radical Cystectomy

For muscle-invasive bladder cancer, radical cystectomy involves complete removal of the bladder along with nearby lymph nodes. In men, this includes removal of the prostate and seminal vesicles; in women, the uterus, ovaries, and part of the vaginal wall may be removed. The procedure can be performed through open surgery, laparoscopic, or robotic-assisted approaches, each offering specific advantages depending on patient factors.

Technology & Equipment Used

Modern bladder cancer treatment utilises technologies including high-definition cystoscopy systems, blue light cystoscopy for enhanced tumour detection, and robotic surgical systems for precise dissection during radical procedures. Radiation therapy employs intensity-modulated radiation therapy (IMRT) or image-guided radiation therapy (IGRT) for targeted treatment delivery while minimising damage to surrounding tissues.

Pre-Treatment Preparation

Before initiating treatment, patients undergo comprehensive staging evaluations including CT scans, MRI, or PET scans to determine cancer extent. Blood tests assess kidney function, liver function, and overall health status. Patients receiving chemotherapy may require cardiac function testing. Nutritional counselling helps optimise health before treatment. Smoking cessation support is provided as smoking affects treatment outcomes and recovery. Patients meet with various specialists to understand their treatment plan. Pre-operative preparation for surgical candidates includes bowel preparation and antibiotic prophylaxis.

During the Procedure

For TURBT procedures, patients receive either spinal or general anaesthesia before the resectoscope is inserted through the urethra. The urologist systematically examines the bladder, removes all visible tumours, and cauterises the tumour base. Tissue samples are sent for pathological analysis. Radical cystectomy involves general anaesthesia and takes 4-6 hours. The surgical team removes the bladder and creates a urinary diversion using a segment of intestine. Throughout any procedure, vital signs are continuously monitored, and the anaesthesia team ensures patient comfort and stability.

Immediate Post-Treatment

Following TURBT, patients have a urinary catheter for 1-2 days and may notice blood in their urine initially. Pain is minimal and manageable with oral medications. After radical cystectomy, patients spend time in recovery before moving to a hospital room. Multiple drains and tubes are present initially, which are removed progressively as healing occurs. The medical team monitors for complications and begins early mobilisation to prevent blood clots. Patients receive education about their urinary diversion care before discharge, which occurs 5-10 days post-surgery for radical cystectomy.

First 24-48 Hours

After TURBT, patients can return home the same day or after an overnight stay. Drinking plenty of fluids helps flush the bladder and reduce bleeding. Avoiding strenuous activities prevents increased bleeding risk. Following radical cystectomy, patients remain hospitalised with close monitoring of vital signs, urine output, and surgical site. Pain management involves a combination of methods including epidural analgesia or patient-controlled analgesia. Early breathing exercises help prevent pneumonia.

First Week

TURBT patients gradually resume normal activities while avoiding heavy lifting or strenuous exercise. Mild burning during urination and occasional blood-tinged urine may persist. Patients should complete prescribed antibiotics and attend follow-up appointments. Radical cystectomy patients focus on gradually increasing mobility, learning stoma care (if applicable), and managing their new urinary diversion system. Dietary progression from liquids to solid foods occurs under medical supervision.

Long-term Recovery

Complete healing after TURBT occurs within 2-4 weeks, though regular surveillance cystoscopy begins at three months. Following radical cystectomy, full recovery takes 6-12 weeks. Patients adapt to their urinary diversion with ongoing support from stoma nurses or learn to manage a neobladder. Regular oncology follow-ups monitor for recurrence through imaging and blood tests. Many patients benefit from support groups and counselling to address psychological aspects of cancer treatment and body image changes.

Effective treatment of urothelial bladder cancer offers significant benefits for patient health and quality of life. For non-muscle invasive disease, bladder-preserving treatments maintain normal urinary function while effectively controlling cancer. Many patients with early-stage disease achieve long-term disease-free survival with appropriate treatment and surveillance. TURBT combined with intravesical therapy can prevent progression to muscle-invasive disease in responsive patients.

For muscle-invasive bladder cancer, modern surgical techniques and urinary diversions allow patients to maintain active lifestyles post-treatment. Continent urinary diversions provide good cosmetic results and eliminate the need for external collection bags in suitable candidates. Multimodal therapy combining surgery with chemotherapy improves survival rates compared to surgery alone. Participation in regular surveillance protocols enables early detection and treatment of recurrences, improving long-term outcomes. Many patients successfully return to work and recreational activities following recovery.

Common Side Effects

Following TURBT, patients commonly experience temporary blood in urine, mild burning during urination, and increased urinary frequency. These resolve within days to weeks. Intravesical BCG therapy may cause flu-like symptoms, bladder irritation, and urinary urgency lasting 24-48 hours after each treatment. Chemotherapy side effects vary by agent but may include fatigue, nausea, hair loss, and increased infection risk. These are manageable with supportive medications and resolve after treatment completion.

Rare Complications

Serious complications from TURBT include bladder perforation (occurring in less than 2% of cases), significant bleeding requiring transfusion, or urinary tract infection progressing to sepsis. Radical cystectomy carries surgical risks including blood clots, wound infection, bowel obstruction, or anastomotic leak. Long-term complications may include erectile dysfunction in men, urinary incontinence with neobladder reconstruction, or kidney function changes. BCG therapy rarely causes systemic BCG infection requiring anti-tuberculosis treatment.

Risk minimisation occurs through careful patient selection, meticulous surgical technique, and appropriate post-operative monitoring. Experienced urologists employ established protocols to identify and manage complications promptly when they occur.

Treatment costs for urothelial bladder cancer vary based on disease stage and required interventions. Initial diagnostic procedures including cystoscopy and imaging studies form the foundation of treatment planning. TURBT procedures and intravesical therapy for non-muscle invasive disease incur lower costs than radical surgery. Radical cystectomy with urinary diversion represents a major surgical procedure with associated hospitalisation and recovery costs.

Ongoing expenses include regular surveillance cystoscopy, imaging studies, and laboratory tests. Patients requiring systemic chemotherapy or immunotherapy face additional medication costs. Stoma supplies for patients with ileal conduits represent a recurring expense. The total treatment package includes surgeon fees, anaesthesia charges, hospital stays, pathology services, and follow-up care. Quality cancer care involves multidisciplinary teams, which impacts overall costs but supports comprehensive treatment. Consulting a bladder specialist in Singapore provides personalised cost estimates based on individual treatment needs.